V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310003699 | 310001549 | 1.71 | 66 | Palliative (P) | 2018-08-26 | 2018-08-27 | GEMCITABINE | 02 | N | 310018476 | GEMCITABINE |
| 310003700 | 310001550 | null | null | null | 2014-06-11 | 2014-06-20 | Liposomal Doxorubicin (Caelyx) | null | null | 310018479 | LIPOSOMAL DOXORUBICIN |
| 310003701 | 310006674 | 1.58 | null | Palliative (P) | 2015-08-29 | 2015-09-04 | ECX | N | null | 310018482 | ECX |
| 310003702 | 310001551 | 1.59 | 80.2 | Palliative (P) | 2014-06-01 | 2014-06-20 | ECX | 02 | N | 310018484 | ECX |
| 310003703 | 310001552 | 1.7 | 30 | null | 2013-11-14 | 2013-11-14 | Cisplatin + Docetaxel +Fluorouracil | N | N | 310018485 | HYDROXYCARBAMIDE |
| 310003704 | 310001553 | null | 56.7 | Adjuvant (A) | 2017-06-11 | 2017-06-20 | Liposomal Doxorubicin 50mg/m2 | 02 | N | 310018486 | BCG |
| 310003705 | 310001553 | 1.6 | 129 | Neo-adjuvant (N) | null | 2015-02-14 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 2 | N | 310018486 | NOT MATCHED |
| 310003706 | 310009094 | 0 | 52 | Disease modification (D) | 2012-08-04 | 2012-08-19 | Rituximab | N | N | 310018490 | HYDROXYCARBAMIDE |
| 310003707 | 310009094 | 1.83 | 82.4 | Palliative (P) | 2016-03-07 | 2016-04-08 | ICON8 TRIAL | N | N | 310018490 | BEXAROTENE |
| 310003708 | 310009094 | null | 11.2 | Palliative (P) | 2015-11-26 | 2015-11-26 | IPILIMUMAB + NIVOLUMAB | 02 | N | 310018490 | IPILIMUMAB + NIVOLUMAB |
| 310003709 | 310001554 | 1.19 | 113 | Palliative (P) | 2017-08-19 | 2017-08-22 | Rituximab | null | null | 310018496 | EOX |
| 310003710 | 310006676 | null | 83.6 | Neo-adjuvant (N) | 2018-03-24 | 2018-03-25 | ECX | N | N | 310018497 | ECX |
| 310003711 | 310006676 | 0 | 68 | Curative (C) | 2014-05-11 | 2014-05-11 | Rituximab | N | N | 310018497 | DACARBAZINE |
| 310003712 | 310001555 | 1.6 | 77 | Palliative (P) | 2015-10-19 | 2015-10-23 | GEMCITABINE | Y | null | 310018500 | GEMCITABINE |
| 310003713 | 310001556 | 1.77 | null | Not known (9) | 2017-04-18 | 2017-04-29 | GEMCITABINE | N | N | 310018501 | GEMCITABINE |
| 310003714 | 310006677 | 1.84 | 0 | Neo-adjuvant (N) | null | 2013-06-18 | ECX | N | N | 310018502 | ECX |
| 310003715 | 310006677 | 1.52 | 94 | Curative (C) | 2016-01-13 | 2016-01-21 | CHOEP | N | N | 310018502 | CHOEP |
| 310003716 | 310001557 | null | 58.9 | Palliative (P) | null | 2018-01-10 | Dacarbazine | N | N | 310018505 | IMATINIB |
| 310003717 | 310001558 | 1.6 | 76.2 | Palliative (P) | 2017-12-19 | 2018-01-04 | ECX | N | N | 310018507 | ECX |
| 310003721 | 310001559 | 1.88 | 66.4 | Palliative (P) | 2015-03-05 | 2015-03-05 | IPILIMUMAB + NIVOLUMAB | N | N | 310018513 | IPILIMUMAB + NIVOLUMAB |
| 310003722 | 310001559 | 0 | 91.2 | null | null | 2017-01-05 | Mitomycin Intravesical | 02 | N | 310018513 | ICON TRIAL |
| 310003723 | 310001559 | 1.72 | 59.4 | Palliative (P) | 2018-01-03 | 2018-02-11 | EOX | N | N | 310018513 | CISPLATIN + ETOPOSIDE |
| 310003724 | 310010359 | 1.71 | 86.2 | null | null | 2016-11-12 | CHOEP - 21 days | N | N | 310018516 | CHOEP |
| 310003725 | 310010359 | 0 | 109.4 | Neo-adjuvant (N) | 2014-10-19 | 2014-10-25 | CISPLATIN + FLUOROURACIL | 99 | N | 310018516 | DACARBAZINE |
| 310003726 | 310011445 | 1.6 | null | Neo-adjuvant (N) | 2014-05-12 | 2014-05-13 | BCG Intravesical | 2 | N | 310018518 | PACLITAXEL |
| 310003727 | 310011445 | 1.68 | 75.8 | Adjuvant (A) | 2014-05-22 | 2014-05-24 | BCG Intravesical | N | N | 310018518 | BCG |
| 310003728 | 310011795 | 1.5 | null | Disease modification (D) | 2018-01-02 | 2018-01-02 | CHOEP - 21 days | N | N | 310018522 | PACLITAXEL |
| 310003729 | 310011872 | 1.52 | 67 | Palliative (P) | 2018-01-25 | 2018-02-14 | Vemurafenib | N | N | 310018525 | ICON TRIAL |
| 310003730 | 310001560 | 1.57 | 58.1 | Adjuvant (A) | 2015-10-20 | 2015-11-13 | Vemurafenib | N | N | 310018527 | ICON TRIAL |
| 310003731 | 310001560 | null | 66 | Palliative (P) | 2013-12-17 | 2013-12-25 | Bexarotene | N | N | 310018527 | VEMURAFENIB |
| 310003732 | 310001560 | 0 | null | Palliative (P) | 2013-11-24 | 2013-11-24 | IMATINIB | 02 | N | 310018527 | IMATINIB |
| 310003733 | 310001560 | 1.61 | 74.7 | Disease modification (D) | 2017-02-25 | 2017-02-27 | EOX | N | N | 310018527 | HYDROXYCARBAMIDE |
| 310003734 | 310001561 | 1.61 | 72.4 | Palliative (P) | 2017-09-01 | 2017-09-01 | Capecitabine + Cisplatin | N | N | 310018533 | CISPLATIN + FLUOROURACIL |
| 310003735 | 310001561 | 1.69 | null | Palliative (P) | 2014-08-31 | 2014-08-31 | ECX | N | N | 310018533 | ECX |
| 310003736 | 310001562 | 1.73 | null | Neo-adjuvant (N) | 2017-01-11 | 2017-02-02 | Oxaliplatin + Modified de Gramont | N | null | 310018536 | CISPLATIN + FLUOROURACIL |
| 310003737 | 310001563 | 1.6 | 0 | null | null | 2017-07-16 | EOX | N | N | 310018537 | ICON TRIAL |
| 310003738 | 310001563 | 1.6 | null | null | 2017-06-04 | 2017-06-05 | GEMCITABINE | N | N | 310018537 | GEMCITABINE |
| 310003739 | 310001564 | 1.74 | 79 | Neo-adjuvant (N) | 2015-12-09 | 2015-12-17 | Bevacizumab+Carbo+Pacliaxel | N | N | 310018541 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310003740 | 310001564 | 1.6 | 50.4 | Disease modification (D) | 2012-10-14 | 2014-07-29 | Capecitabine + Oxaliplatin 21day | N | N | 310018541 | EOX |
| 310003741 | 310009100 | 1.79 | null | Adjuvant (A) | 2016-08-17 | 2016-09-01 | CISPLATIN + FLUOROURACIL | null | null | 310018546 | PACLITAXEL |
| 310003742 | 310001565 | null | 80.3 | Curative (C) | 2017-02-27 | 2017-02-27 | CISPLATIN + FLUOROURACIL | Y | null | 310018548 | VEMURAFENIB |
| 310003745 | 310009101 | 1.78 | null | Disease modification (D) | 2014-05-15 | 2014-05-22 | Capecitabine + Oxaliplatin 21day | N | null | 310018555 | OXALIPLATIN + MDG |
| 310003746 | 310001567 | 1.57 | 74.4 | Palliative (P) | null | 2017-05-15 | Bexarotene | N | N | 310018567 | MITOMYCIN INTRAVESICULAR |
| 310003747 | 310001567 | 1.61 | 63.8 | Neo-adjuvant (N) | 2016-02-07 | 2016-02-28 | GEM-P | N | N | 310018567 | ICON TRIAL |
| 310003748 | 310009102 | null | 92.3 | Palliative (P) | 2014-10-30 | 2014-10-30 | ECX | N | N | 310018570 | ECX |
| 310003749 | 310001568 | 1.5 | null | Disease modification (D) | 2015-06-14 | 2015-06-14 | Oxaliplatin + Modified de Gramont | N | N | 310018574 | CISPLATIN + FLUOROURACIL |
| 310003750 | 310001568 | 1.6 | 48.1 | null | 2016-09-21 | 2016-09-29 | Vemurafenib | N | N | 310018574 | HYDROXYCARBAMIDE |
| 310003751 | 310001569 | 1.7 | 70.1 | Palliative (P) | 2015-10-02 | 2015-10-03 | IPILIMUMAB + NIVOLUMAB | N | N | 310018581 | IPILIMUMAB + NIVOLUMAB |
| 310003752 | 310001569 | 1.83 | null | null | null | 2016-11-30 | Mitomycin Intravesical | N | N | 310018581 | CAPECITABINE + OXALIPLATIN |
| 310003753 | 310009103 | 1.56 | null | Curative (C) | 2015-04-19 | 2015-05-22 | CHOEP - 14 days | 02 | null | 310018583 | CHOEP |